Compare · DCPH vs XFOR
DCPH vs XFOR
Side-by-side comparison of Deciphera Pharmaceuticals Inc. (DCPH) and X4 Pharmaceuticals Inc. (XFOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. DCPH focuses on Biotechnology: Pharmaceutical Preparations, while XFOR focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- DCPH is the larger of the two at $455.0M, about 1.2x XFOR ($374.4M).
- XFOR has hit the wire 9 times in the past 4 weeks while DCPH has been quiet.
- DCPH has more recent analyst coverage (18 ratings vs 8 for XFOR).
- Company
- Deciphera Pharmaceuticals Inc.
- X4 Pharmaceuticals Inc.
- Price
- $25.61+0.18%
- $3.98-2.09%
- Market cap
- $455.0M
- $374.4M
- 1M return
- -
- -5.47%
- 1Y return
- -
- +0.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2017
- News (4w)
- 0
- 9
- Recent ratings
- 18
- 8
Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
X4 Pharmaceuticals Inc.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest DCPH
- SEC Form 15-12G filed by Deciphera Pharmaceuticals Inc.
- SEC Form EFFECT filed by Deciphera Pharmaceuticals Inc.
- EVP & Chief Medical Officer Sherman Matthew L was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Kelly Thomas Patrick was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Development Officer Pitman Jama was granted 20,163 shares and returned 53,951 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Friedman Franklin Stuart closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Kelley Susan L.
- EVP & Chief Scientific Officer Dhanak Dashyant was granted 25,913 shares and returned 184,088 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Martin John Richard
- Chief Commercial Officer Martin Daniel C. was granted 20,163 shares and returned 43,951 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest XFOR
- Leerink Partners initiated coverage on X4 Pharmaceuticals with a new price target
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- SEC Form EFFECT filed by X4 Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.
- Amendment: X4 Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Chief Financial Officer Kirske David sold $72,820 worth of shares (16,961 units at $4.29), decreasing direct ownership by 9% to 176,293 units (SEC Form 4)
- SEC Form 144 filed by X4 Pharmaceuticals Inc.
- X4 Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form S-3 filed by X4 Pharmaceuticals Inc.